ALLMedicine™ Prostate Cancer Center
Research & Reviews 85,785 results
https://doi.org/10.1186/s13046-021-01875-0 10.1038/nrurol.2012.185 10.1177/1756287213495915 10.1007/s13402-016-0268-6 10.1001/jama.296.19.2336 10.1093/jnci/djp122 10.1001/jama.280.11.969 10.1038/nrurol.2016.193 10.1073/pnas.0804549105 10.1373/clinchem.2010.147405 10.1186/s12885-016-2442-7 10.1111/bju.13157 10.1093/bioinformatics/btx647 10.1186/s13059-014-0550-8 10.1038/s41598-019-46872-8 10.1016/j.addr.2014.09.001 10.1002/pros.22495 10.1007/s13277-014-1638-1 10.1002/pros.23485 10.1007/s13346-013-0169-4 10.1158/0008-5472.CAN-10-1229 10.1038/s41598-018-24424-w 10.1371/journal.pone.0179543 10.3233/CBM-170124) 10.1038/emm.2014.63 10.3390/jcm4071369
Journal of Experimental & Clinical Cancer Research : CR; Giglio S, De Nunzio C et. al.
Feb 24th, 2021 - A prostate cancer diagnosis is based on biopsy sampling that is an invasive, expensive procedure, and doesn't accurately represent multifocal disease. To establish a model using plasma miRs to distinguish Prostate cancer patients from non-cancer c...
https://doi.org/10.1158/0008-5472.CAN-20-1624
Cancer Research; Matthias J, Engelhardt J et. al.
Feb 24th, 2021 - Targeted imaging and therapy approaches based on novel prostate-specific membrane antigen (PSMA) inhibitors have fundamentally changed the treatment regimen of prostate cancer. However, the exact mechanism of PSMA inhibitor internalization has not...
https://doi.org/10.1158/1078-0432.CCR-20-4573
Clinical Cancer Research : an Official Journal of the Ame... Morris MJ, Rowe SP et. al.
Feb 24th, 2021 - Current FDA-approved imaging modalities are inadequate for localizing prostate cancer biochemical recurrence (BCR). 18F-DCFPyL is a highly selective, small-molecule PSMA-targeted PET radiotracer. CONDOR was a prospective study designed to determin...
https://doi.org/10.1038/s41467-021-21287-0 10.3322/caac.21262 10.1056/NEJMoa1606220 10.1056/NEJMoa1807801 10.1056/NEJMoa0810095 10.1056/NEJMoa1012348 10.1001/jama.2018.0161 10.3322/caac.20066 10.1126/scitranslmed.3001861 10.1002/pros.23200 10.1038/ng.2563 10.1373/clinchem.2018.286658 10.1038/s41588-018-0142-8 10.1038/s41588-019-0379-x 10.1002/gepi.22166 10.1038/538161a 10.3322/caac.21340 10.1002/cncr.30687 10.1093/hmg/ddx253 10.1146/annurev.genom.9.081307.164258 10.1002/cncr.32702 10.1158/1055-9965.EPI-19-1527 10.1053/j.seminoncol.2016.08.001 10.1016/j.urology.2014.02.035 10.1001/jamaoncol.2018.0174 10.7326/0003-4819-152-1-201001050-00005 10.1056/NEJMoa031994 10.1136/jmedgenet-2018-105313 10.1038/s41576-018-0018-x 10.1002/ijc.29066 10.1158/1055-9965.EPI-12-0598 10.1158/1055-9965.EPI-16-0106 10.1158/1055-9965.EPI-08-0317 10.1214/aos/1176344552 10.1023/A:1009691327335 10.1534/genetics.114.164350
Nature Communications; Huynh-Le MP, Fan CC et. al.
Feb 24th, 2021 - Genetic models for cancer have been evaluated using almost exclusively European data, which could exacerbate health disparities. A polygenic hazard score (PHS1) is associated with age at prostate cancer diagnosis and improves screening accuracy in...
https://doi.org/10.1038/s41585-021-00432-w 10.1016/j.eururo.2009.02.028 10.1016/j.eururo.2013.12.062 10.1001/jama.2018.19941 10.1111/his.13712 10.21037/tau.2018.03.02 10.1016/j.eururo.2016.06.007 10.1016/j.juro.2015.02.2938 10.1001/jamaoncol.2016.0170 10.1001/jama.1994.03510290050036 10.1016/j.eururo.2007.11.057 10.1002/cncr.20586 10.1016/j.juro.2008.11.107 10.1016/j.juro.2017.10.029 10.1016/j.juro.2014.04.013 10.1200/JCO.2002.03.061 10.1016/j.eururo.2012.05.049 10.1016/j.urology.2007.11.094 10.1016/j.urology.2013.12.054 10.1016/j.juro.2013.09.029 10.1002/cncr.32709 10.1016/j.juro.2010.10.057 10.1001/jamaoncol.2017.1879 10.1016/j.eururo.2013.03.033 10.1016/j.juro.2016.06.102 10.1016/j.juro.2018.04.058 10.1200/JCO.2015.62.5764 10.1097/PAS.0000000000000235 10.1016/j.anndiagpath.2015.10.013 10.1038/modpathol.2014.116 10.1016/j.ejca.2016.07.012 10.1016/j.euf.2017.03.004 10.1038/s41391-018-0093-2 10.1007/s00261-016-0975-5 10.1016/S1078-1439(03)00031-0 10.1111/j.1464-410X.2009.08938.x 10.1016/j.eururo.2007.08.006 10.1016/j.juro.2014.02.005 10.1016/j.eururo.2008.11.051 10.1016/S0140-6736(16)32401-1 10.1056/NEJMoa1801993 10.1016/j.eururo.2015.08.052 10.1016/j.juro.2018.05.003 10.1111/bju.13624 10.1038/s41391-018-0111-4 10.1111/bju.14916 10.1097/JU.0000000000000693 10.1016/j.eururo.2019.10.007 10.1016/j.juro.2017.07.070 10.1038/nrurol.2016.26 10.21037/tau.2017.12.26 10.1007/s13402-016-0268-6 10.1016/j.juro.2015.01.091 10.1016/j.purol.2011.09.009 10.1016/j.eururo.2014.07.034 10.1111/bju.14098 10.1111/bju.15101 10.1016/j.eururo.2014.10.021 10.1016/j.eururo.2016.11.017 10.1001/jamaoncol.2017.0177 10.1158/1078-0432.CCR-12-3283 10.1038/s41391-018-0124-z 10.1038/pcan.2017.16 10.1016/j.eururo.2016.04.012 10.1001/jamaoncol.2016.0097 10.1016/j.eururo.2018.08.019 10.1016/j.juro.2012.08.219 10.2741/4191 10.1002/path.2559 10.1016/j.juro.2015.09.072 10.1200/JCO.2012.46.4396 10.2217/pme-2019-0084 10.1111/bju.12789 10.1002/cncr.30665 10.1038/s41391-019-0167-9 10.1016/j.eururo.2014.05.004 10.1200/JCO.19.02267 10.1016/j.juro.2014.09.094 10.1016/j.juro.2010.09.095
Nature Reviews. Urology; Liu JL, Patel HD et. al.
Feb 24th, 2021 - Early identification and management of prostate cancer completely changed with the discovery of prostate-specific antigen. However, improved detection has also led to overdiagnosis and consequently overtreatment of patients with low-risk disease. ...
Guidelines 391 results
https://doi.org/10.1016/j.prro.2020.10.002
Practical Radiation Oncology; Zietman AL,
Dec 14th, 2020 - ASTRO Editorial: The AUA-ASTRO-SUO Advanced Prostate Cancer Guidelines: A Continued but Changing Role for the Radiation Oncologist.|2020|Zietman AL, ,|
https://doi.org/10.1097/JU.0000000000001376
The Journal of Urology; Lowrance WT, Breau RH et. al.
Sep 22nd, 2020 - The summary presented herein represents Part II of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with castration-resistant disease. Please refer ...
https://doi.org/10.1097/JU.0000000000001375
The Journal of Urology; Lowrance WT, Breau RH et. al.
Sep 22nd, 2020 - The summary presented herein represents Part I of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with biochemical recurrence without metastatic di...
https://doi.org/10.1016/j.prro.2020.06.009
Practical Radiation Oncology; Bauman GS, Jani AB
Sep 6th, 2020 - American Society for Radiation Oncology Editorial: Rapidly Evolving Technologies Related to Imaging Strategies for Advanced Prostate Cancer.|2020|Bauman GS,Jani AB,|
https://doi.org/10.1002/pros.24053
The Prostate REFERENCES; Shore ND, Drake CG et. al.
Aug 11th, 2020 - Advanced prostate cancer (PC) patients, especially those with metastatic prostate cancer (mPC), often require complex management pathways. Despite the publication of clinical practice guidelines by leading urological and oncological organizations ...
Drugs 337 results see all →
Clinicaltrials.gov 93,515 results
https://doi.org/10.1186/s13046-021-01875-0 10.1038/nrurol.2012.185 10.1177/1756287213495915 10.1007/s13402-016-0268-6 10.1001/jama.296.19.2336 10.1093/jnci/djp122 10.1001/jama.280.11.969 10.1038/nrurol.2016.193 10.1073/pnas.0804549105 10.1373/clinchem.2010.147405 10.1186/s12885-016-2442-7 10.1111/bju.13157 10.1093/bioinformatics/btx647 10.1186/s13059-014-0550-8 10.1038/s41598-019-46872-8 10.1016/j.addr.2014.09.001 10.1002/pros.22495 10.1007/s13277-014-1638-1 10.1002/pros.23485 10.1007/s13346-013-0169-4 10.1158/0008-5472.CAN-10-1229 10.1038/s41598-018-24424-w 10.1371/journal.pone.0179543 10.3233/CBM-170124) 10.1038/emm.2014.63 10.3390/jcm4071369
Journal of Experimental & Clinical Cancer Research : CR; Giglio S, De Nunzio C et. al.
Feb 24th, 2021 - A prostate cancer diagnosis is based on biopsy sampling that is an invasive, expensive procedure, and doesn't accurately represent multifocal disease. To establish a model using plasma miRs to distinguish Prostate cancer patients from non-cancer c...
https://doi.org/10.1158/0008-5472.CAN-20-1624
Cancer Research; Matthias J, Engelhardt J et. al.
Feb 24th, 2021 - Targeted imaging and therapy approaches based on novel prostate-specific membrane antigen (PSMA) inhibitors have fundamentally changed the treatment regimen of prostate cancer. However, the exact mechanism of PSMA inhibitor internalization has not...
https://doi.org/10.1158/1078-0432.CCR-20-4573
Clinical Cancer Research : an Official Journal of the Ame... Morris MJ, Rowe SP et. al.
Feb 24th, 2021 - Current FDA-approved imaging modalities are inadequate for localizing prostate cancer biochemical recurrence (BCR). 18F-DCFPyL is a highly selective, small-molecule PSMA-targeted PET radiotracer. CONDOR was a prospective study designed to determin...
https://doi.org/10.1038/s41467-021-21287-0 10.3322/caac.21262 10.1056/NEJMoa1606220 10.1056/NEJMoa1807801 10.1056/NEJMoa0810095 10.1056/NEJMoa1012348 10.1001/jama.2018.0161 10.3322/caac.20066 10.1126/scitranslmed.3001861 10.1002/pros.23200 10.1038/ng.2563 10.1373/clinchem.2018.286658 10.1038/s41588-018-0142-8 10.1038/s41588-019-0379-x 10.1002/gepi.22166 10.1038/538161a 10.3322/caac.21340 10.1002/cncr.30687 10.1093/hmg/ddx253 10.1146/annurev.genom.9.081307.164258 10.1002/cncr.32702 10.1158/1055-9965.EPI-19-1527 10.1053/j.seminoncol.2016.08.001 10.1016/j.urology.2014.02.035 10.1001/jamaoncol.2018.0174 10.7326/0003-4819-152-1-201001050-00005 10.1056/NEJMoa031994 10.1136/jmedgenet-2018-105313 10.1038/s41576-018-0018-x 10.1002/ijc.29066 10.1158/1055-9965.EPI-12-0598 10.1158/1055-9965.EPI-16-0106 10.1158/1055-9965.EPI-08-0317 10.1214/aos/1176344552 10.1023/A:1009691327335 10.1534/genetics.114.164350
Nature Communications; Huynh-Le MP, Fan CC et. al.
Feb 24th, 2021 - Genetic models for cancer have been evaluated using almost exclusively European data, which could exacerbate health disparities. A polygenic hazard score (PHS1) is associated with age at prostate cancer diagnosis and improves screening accuracy in...
https://doi.org/10.1038/s41585-021-00432-w 10.1016/j.eururo.2009.02.028 10.1016/j.eururo.2013.12.062 10.1001/jama.2018.19941 10.1111/his.13712 10.21037/tau.2018.03.02 10.1016/j.eururo.2016.06.007 10.1016/j.juro.2015.02.2938 10.1001/jamaoncol.2016.0170 10.1001/jama.1994.03510290050036 10.1016/j.eururo.2007.11.057 10.1002/cncr.20586 10.1016/j.juro.2008.11.107 10.1016/j.juro.2017.10.029 10.1016/j.juro.2014.04.013 10.1200/JCO.2002.03.061 10.1016/j.eururo.2012.05.049 10.1016/j.urology.2007.11.094 10.1016/j.urology.2013.12.054 10.1016/j.juro.2013.09.029 10.1002/cncr.32709 10.1016/j.juro.2010.10.057 10.1001/jamaoncol.2017.1879 10.1016/j.eururo.2013.03.033 10.1016/j.juro.2016.06.102 10.1016/j.juro.2018.04.058 10.1200/JCO.2015.62.5764 10.1097/PAS.0000000000000235 10.1016/j.anndiagpath.2015.10.013 10.1038/modpathol.2014.116 10.1016/j.ejca.2016.07.012 10.1016/j.euf.2017.03.004 10.1038/s41391-018-0093-2 10.1007/s00261-016-0975-5 10.1016/S1078-1439(03)00031-0 10.1111/j.1464-410X.2009.08938.x 10.1016/j.eururo.2007.08.006 10.1016/j.juro.2014.02.005 10.1016/j.eururo.2008.11.051 10.1016/S0140-6736(16)32401-1 10.1056/NEJMoa1801993 10.1016/j.eururo.2015.08.052 10.1016/j.juro.2018.05.003 10.1111/bju.13624 10.1038/s41391-018-0111-4 10.1111/bju.14916 10.1097/JU.0000000000000693 10.1016/j.eururo.2019.10.007 10.1016/j.juro.2017.07.070 10.1038/nrurol.2016.26 10.21037/tau.2017.12.26 10.1007/s13402-016-0268-6 10.1016/j.juro.2015.01.091 10.1016/j.purol.2011.09.009 10.1016/j.eururo.2014.07.034 10.1111/bju.14098 10.1111/bju.15101 10.1016/j.eururo.2014.10.021 10.1016/j.eururo.2016.11.017 10.1001/jamaoncol.2017.0177 10.1158/1078-0432.CCR-12-3283 10.1038/s41391-018-0124-z 10.1038/pcan.2017.16 10.1016/j.eururo.2016.04.012 10.1001/jamaoncol.2016.0097 10.1016/j.eururo.2018.08.019 10.1016/j.juro.2012.08.219 10.2741/4191 10.1002/path.2559 10.1016/j.juro.2015.09.072 10.1200/JCO.2012.46.4396 10.2217/pme-2019-0084 10.1111/bju.12789 10.1002/cncr.30665 10.1038/s41391-019-0167-9 10.1016/j.eururo.2014.05.004 10.1200/JCO.19.02267 10.1016/j.juro.2014.09.094 10.1016/j.juro.2010.09.095
Nature Reviews. Urology; Liu JL, Patel HD et. al.
Feb 24th, 2021 - Early identification and management of prostate cancer completely changed with the discovery of prostate-specific antigen. However, improved detection has also led to overdiagnosis and consequently overtreatment of patients with low-risk disease. ...
News 6,531 results
https://www.medscape.com/viewarticle/946211
Feb 23rd, 2021 - NEW YORK (Reuters Health) - Dose-intensified salvage radiotherapy is not superior to conventional dose salvage RT and is associated with increased late rectal toxicity in patients with biochemical recurrence of prostate cancer after prostatectomy,...
https://www.medscape.com/viewarticle/945928
Feb 22nd, 2021 - Patients with prostate cancer have a right to expect that their screening, diagnosis, and treatment are supported by evidence-based science. But how well does the urology community measure up when it comes to claims that standard-of-care practices...
https://www.medscape.com/viewarticle/946187
Feb 21st, 2021 - Could imaging be used for routine screening for prostate cancer in healthy men — similar to mammography for breast cancer screening? A quick scan — with 15-minute, contrast-free MRI — detected more clinically significant prostate tumors than the u...
https://www.medscape.com/viewarticle/946111
Feb 18th, 2021 - The results of a trial led by Medical Detection Dogs in Milton Keynes suggest that trained dogs can detect advanced prostate cancer in urine samples with high specificity and sensitivity. The study, published in PLoS One, tested the clinical fea...
https://www.medscape.com/viewarticle/945995
Feb 17th, 2021 - (Reuters Health) - Daily relugolix therapy cuts menstrual bleeding by at least half without affecting bone density in 71% of women with uterine fibroids, according to results from the LIBERTY 2 trial, published by The New England Journal of Medici...
